Comparison of patients with and without relapse
| Relapse (n=13) | No relapse (n=19) | |
|---|---|---|
| Unless otherwise indicated, results are means (SD). | ||
| *Samples obtained at diagnosis or within three days after initiation of acyclovir treatment were used. | ||
| **p=0.04 by Fisher’s exact test. ***p=0.03 by χ2 test. Bold letters indicate significantly different results. | ||
| Birth weight (g) | 2890 (580) | 2960 (510) |
| Gestational age (weeks) | 38.0 (2.7) | 38.2 (2.4) |
| Day of onset | 6.9 (5.2) | 6.6 (5.0) |
| Clinical type of infection | ||
| Disseminated (%) | 15.4 | 26.3 |
| Central nervous system (%) | 46.2 | 36.8 |
| Skin, eye, and/or mouth (%) | 38.5 | 36.8 |
| Viral load* | ||
| Serum (copies/ml) | 102.3 (3.0) | 102.2 (2.4) |
| Cerebrospinal fluid (copies/ml) | 102.2 (1.7) | 101.8 (2.4) |
| Viral type | ||
| Type 1 (%) | 38.5 | 78.9 |
| Type 2 (%) | 53.8 ** | 21.1 ** |
| Unknown (%) | 7.7 | 0.0 |
| Initial acyclovir treatment | ||
| Start after onset (days) | 4.3 (3.1) | 3.9 (2.2) |
| Dose (mg/kg) | 34.2 (6.7) | 32.4 (7.5) |
| Duration (days) | 15.2 (6.1) | 16.9 (6.3) |
| Prognosis | ||
| Normal (%) | 61.5 *** | 84.2 *** |
| Mildly disabled (%) | 0.0 *** | 15.8 *** |
| Severely disabled (%) | 23.1 *** | 0.0 *** |
| Unknown (%) | 15.4 | 0.0 |